Celemin Hepa 8%

Dong-A Pharm. Co. Ltd. -  started in 1932 as a wholesaler of pharmaceuticals and sanitary products at a small office. Though small in size, it was a start with a big aspiration of providing good pharmaceuticals to suffering people.

After Korean war, Dong - A introduced a variety of then latest pharmaceutical manufacturing equipment and machinery from Germany to produce pharmaceuticals like penicillin and streptomycin, Kanamycin, a broad-spectrum antibiotic agent, was produced in 1959.

Since then, Dong – A has made its efforts toward building a healthy society without diseases by introducing various new products ranging from a variety of anti-cancer agents, diagnostic reagents to products utilizing the recombinant DNA technique, etc. They have also participated in the environmental business with wider view and considering nature as the source of life of mankind.

After 68 years it became Korea’s no. 1 Pharmaceutical Company, outgrowing the more popular Korean Green Cross.

Wants to know more about Dong-A?

CJ Corporation - launched its pharmaceutical business in 1984 with a vision to be a market leader in pharmaceutical industry based on fermentation and synthetic technology.

The Pharmaceutical Division of the R&D Institute of Science and Technology is engaged in the discovery and development of novel small molecule and biological compounds in the areas of oncology, vaccines, immunology, inflammation and other therapeutic areas of high unmet need and commercial potential. CJ Corp. is the largest pharmaceutical, food and entertainment company in Korea. It is also a top 10 Korean company according to Far Eastern Economic Review (Dec. 30, 1999 issue).

CJ Corp. interacts with overseas customers in over sixty countries through a network of thirty-two offices around the world. Currently, ten are local subsidiaries, and the company plans to continue upgrading more offices to subsidiary status as a part of an  aggressive globalization program. 

Wants to know more about CJ Corporation?

SK Chemicals - the Korea’s leading chemicals company-SK Chemicals has been developing environment-friendly chemical products that make our lives healthier and safer with an aim to create harmony between men and nature since 1969.

After the spin-off of its textile business in 2000, SK Chemicals made a fresh start and established a long-term vision to focus on specialty chemicals and life science. SK Chemicals was the leader to develop high-performance PETG resin (SKYGREEN), and is making rapid and steady progress in the polyurethane business. SK Chemicals is going the extra mile to maximize corporate value by showing results in current projects and developing new businesses.

SK Chemicals is reporting continued sales growth in the area of life science with the brands like Sunpla- Korea’s first anti-cancer drug, Trast- the number one selling arthritis patch, and Joins-Korea’s first natural herb product. SK Chemicals will continue to make the best products through the synergy of R&D-production-sales network consisted of Life Science Research Center and subsidiaries companies.

SK Chemicals continues to implement its global strategies and as a result, it has recently established production facilities in Indonesia and China. The mid- to long-term plan includes the opening of the plant in Poland scheduled for completion in 2005 while the main goal is to expand businesses in China and ensure global competitiveness in all business areas.

Based on stable revenues from its main business areas of petrochemical and resin, SK Chemicals will become one of the leading companies in the 21st century by concentrating resources in specialty chemicals for environmental, industrial and IT materials as well as in the area of biotech and life science for developing synthetic and natural drugs.

Wants to know more about SK Chemicals?

Emcure Pharmaceuticals Ltd. - established in 1981, Emcure was born out of the vision to create a healthcare company that would address the vast healthcare needs. Our commitment and drive have propelled our growth from a single manufacturing facility during the genesis, to a range of world class manufacturing facilities spread across API, formulations and biotechnology.

What began with a single manufacturing facility at Pune, has today rapidly grown into a set of world class manufacturing facilities and one of the top Indian pharmaceutical corporates in the domestic industry.

Headquartered in Pune, India, Emcure is today a vertically integrated pharmaceutical company with infrastructure, skills and resources that are at par with the best in the world. Our strengths span research to the manufacturing of APIs, Formulations and Biotechnology.

The Company has carved a niche for itself as a preferred outsourcing partner for some of the largest MNCs both in India and global markets.

Emcure also researches, manufactures and markets formulations under its own brands in the domestic market and exports its own formulations to Asia, Africa, CIS, Europe, Latin America and the Middle East.

In 2006, it received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets. With this approval, the facility has accreditation from US FDA, UK MHRA, WHO Geneva and MCC South Africa.

Today, the Emcure brand stands for quality, competitiveness and transparency. These values have stood us in good stead to carve our image in the industry and build long-term sustainable relationships with our partners.

Emcure is building its pipeline of Chiral and conventional APIs and is emerging as a strong player in the biotechnology front.

Emcure is also very active in dealing with HIV/AIDS concern through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. We took another significant step towards fulfilling our corporate social responsibility by starting ‘Taal’, a pharmacy for HIV/AIDS.

Wants to know more about Emcure Pharmaceuticals?

Claris Lifesciences is an international pharmaceutical company, in the business of manufacturing and marketing of high end injectables with focus on New Drug Delivery Systems for treatment of critical illnesses and diseases.

With emphasis on Research, Technology and Quality, Claris offers a range of unique products and delivery systems in bottles, vials, ampoules, pre-filled syringes, non-PVC/PVC bags and oral dosage forms. The company's strength lies in its know-how and expertise in manufacturing and marketing injectable products. 

Driven by a team of scientists, pharmaceutical experts and management professionals, Claris is powered by a combination of Vision, R&D capabilities, Technological know how, International standards and Manufacturing expertise. 

The company's range of products and delivery systems extends across Enteral and Parenteral Nutrition, Anaesthesia, Blood Products and Plasma Volume Expanders, Anti-infectives, Dialysis and Transplant, Cardiac Care, Infusion Therapy as well as Medical Disposables and Equipment.

Claris enjoys Market Leadership in India. Globally, the company operates in more than 76 countries, through its subsidiaries, offices and marketing/distribution network, and a diverse customer profile covering institutions, major corporate hospitals and international aid agencies.

Wants to know more about Claris?